MedTrace Logo

Steady State Kinetics of l-Methamphetamine and Validation of Sensitivity of Dose Estimation

NCT00829634 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-05-31

No results posted yet for this study

Summary

The intent of this study is to see if the rate that the body breaks down l-methamphetamine (l-MA) could be used as an accurate estimate for the rate that the body breaks down d-methamphetamine (d-MA). l-MA is sold over the counter as a nasal decongestant where as d-MA is the commonly abused form of methamphetamine.

Conditions

  • Nasal Congestion

Interventions

DRUG

l-methamphetamine

5mg of l-methamphetamine per day throughout the 2 week study

DRUG

d-methamphetamine

15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13

Sponsors & Collaborators

  • San Francisco General Hospital

    collaborator OTHER

  • University of California, San Francisco

    collaborator OTHER

  • National Institutes of Health (NIH)

    collaborator NIH

  • California Pacific Medical Center Research Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00829634 on ClinicalTrials.gov